A systematic review and network meta-analysis, which allowed the simultaneous comparison of multiple achieved systolic blood pressure (SBP) levels on clinical outcomes while preserving trial-level treatment randomization, indicates that treating patients to reduce SBP below currently recommended targets may significantly reduce risk of cardiovascular disease (CVD) and all-cause mortality, with the lowest risk at a SBP of 120 to 124 mm Hg. The study included 144 220 patients from 42 trials. In general, there were linear associations between mean achieved SBP and risk of CVD and mortality, with the lowest risk at 120 to 124 mm Hg. Randomized groups with a mean achieved SBP of 120 to 124 mm Hg had a hazard ratio (HR) for major CVD of 0.71, 0.58, 0.46 and 0.36, respectively, compared with randomized groups with a mean achieved SBP of 130 to 134 mm Hg, 140 to 144 mm Hg, 150 to 154 mm Hg, and 160 mm Hg or more. Likewise, randomized groups with a mean achieved SBP of 120 to 124 mm Hg had an HR for all-cause mortality of 0.73, 0.59, 0.51 and 0.47, respectively, compared with randomized groups with a mean achieved SBP of 130 to 134 mm Hg, 140 to 144 mm Hg, 150 to 154 mm Hg, and 160 mm Hg or more. The findings support more intensive control of SBP among adults with hypertension. Source: http://jamanetwork.com/http://jamanetwork.com/
Both clinician-rated and patient-reported outcomes suggested that mindfulness-based stress reduction (MBSR) was well-tolerated with comparable…
The number of individuals with high blood pressure (BP) is increasing worldwide. The trajectory of…
A single combined measure of high-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a)…
A French multicenter, open label, randomized, noninferiority trial suggested that interruption of long-term beta-blocker treatment…
A US prospective cohort study demonstrated that replacement of animal fat with an equivalent amount…
An ongoing UK national prospective program shows remission of type 2 diabetes (T2D) outside of…
This website uses cookies.